C. H. Unnikrishnan - Profile and Journalist Details

Find journalists that align with your industry, location and vision. Unlock C. H. Unnikrishnan's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.

Get connected with journalists today
C. H. Unnikrishnan

C. H. Unnikrishnan

Verified

Consulting Editor, CNBC

Mumbai

Final Covers

Outdoor Gear , Fitness Tech , Consumer Product Reviews , Mobile Tech , Trail Running Shoes , Apparel

Doesn’t Cover

I wouldn't cover sensitive issues like Gender and sexuality

Journalist Type

Seniority Positions

Medium Formats

Content

Total articles 24

  • Natco launches first generic of Hepatitis C drug Sovaldi

    By C. H. Unnikrishnan| Mint@ The price of Sovaldi, developed and patented by Gilead, has been the topic of much debate globally after its launched in 2014. Natco will sell the drug at 19,900 for a bottle of 28 tablets—one-ninetieth of Gilead’s price—in Nepal under the brand name Hepacinat. The price of Sovaldi, developed and patented by Gilead, has been the topic of much debate globally after its launch in 2014.

    By C. H. Unnikrishnan · Mint

    Mar. 09, 2015

  • AB Ventures to start India’s first luxury hospital chain

    By C. H. Unnikrishnan| Mint@ Luxury hospitals is a new concept in India, where the cost of private healthcare is relatively high. Photo: MintLuxury hospitals is a new concept in India, where the cost of private healthcare is relatively high. ABV runs its healthcare services under three key brands—Nucleus Medical and Diagnostics Centre, Lifeline Healthcare and 800 Doctor—and will use the first for its luxury hospital chain. The group has already set up a local unit of Nucleus Medical Centre in Mumbai to test the market.

    By C. H. Unnikrishnan · Mint

    Mar. 02, 2015

  • Natco launches first generic of Hepatitis C drug Sovaldi

    By C. H. Unnikrishnan| Mint@ The price of Sovaldi, developed and patented by Gilead, has been the topic of much debate globally after its launched in 2014. Natco will sell the drug at 19,900 for a bottle of 28 tablets—one-ninetieth of Gilead’s price—in Nepal under the brand name Hepacinat. The price of Sovaldi, developed and patented by Gilead, has been the topic of much debate globally after its launch in 2014.

    By C. H. Unnikrishnan · Mint

    Mar. 09, 2015

As seen in

Company Info

CNBC

CNBC, or the Consumer News and Business Channel, is a prominent global business news television channel that launched on April 17, 1989. Founded by former NBC President Bob Wright, CNBC aims to provide viewers with insights into how business events impact their lives and finances. The network has grown to become the world's leading business news media company, reaching over 450 million consumers each month. CNBC offers a variety of services, including 23 hours of live TV programming each weekday, featuring popular shows like *Squawk Box* and *Fast Money*. It operates a 24/7 digital platform that delivers real-time news, analysis, and market data through its website and mobile apps. Additionally, CNBC provides subscription-based services for exclusive content and hosts numerous business events and conferences for networking among executives and thought leaders. With a global presence and more than 20 bureaus worldwide, CNBC also tailors its content for regional audiences through channels like CNBC Asia and CNBC Europe.

Los Gatos, California, United States